Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study-Reference-Cited by-同舟云学术

Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study

Published:2020-03-25 Issue:4 Volume:58 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Kaniga Koné¹,Aono Akio²,Borroni Emanuele³^ORCID,Cirillo Daniela Maria³^ORCID,Desmaretz Christel⁴,Hasan Rumina⁵⁶,Joseph Lavania⁷,Mitarai Satoshi²,Shakoor Sadia⁵,Torrea Gabriela⁴,Ismail Nazir Ahmed⁷⁸⁹,Omar Shaheed V.⁷

Affiliation:

1. Johnson & Johnson Global Public Health, Titusville, New Jersey, USA

2. Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-tuberculosis Association, Kiyose, Japan

3. Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

4. Department of Biomedical Sciences, Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium

5. Department of Pathology and Laboratory Medicine, The Aga Khan University, Karachi, Pakistan

6. Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London, United Kingdom

7. Center for Tuberculosis, National and WHO Supranational TB Reference Laboratory, National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa

8. Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa

9. Department of Internal Medicine, University of Witwatersrand, Johannesburg, South Africa

Abstract

Drug-resistant tuberculosis persists as a major public health concern. Alongside efficacious treatments, validated and standardized drug susceptibility testing (DST) is required to improve patient care. This multicountry, multilaboratory external quality assessment (EQA) study aimed to validate the sensitivity, specificity, and reproducibility of provisional bedaquiline MIC breakpoints and World Health Organization interim critical concentrations (CCs) for categorizing clinical Mycobacterium tuberculosis isolates as susceptible/resistant to the drug.

Funder

Janssen Pharmaceutica, NV

Bill and Melinda Gates Foundation

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01677-19

Reference35 articles.

1. World Health Organization. 2018. Global tuberculosis report 2018 (WHO/CDS/TB/2018.20). WHO, Geneva, Switzerland. http://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf?ua=1. Accessed 19 June 2019.

2. Molecular Diagnosis of Drug-Resistant Tuberculosis; A Literature Review

3. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

4. Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

5. Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative drug susceptibility testing for Mycobacterium tuberculosis using unassembled sequencing data and machine learning;PLOS Computational Biology;2024-08-05

2. A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug‐Resistant and Extensively Drug‐Resistant Mycobacterium tuberculosis;Journal of Clinical Laboratory Analysis;2024-08

3. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data;Journal of Infection and Public Health;2024-01

4. Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis;Microbiology Spectrum;2023-10-17

5. Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China;Infection and Drug Resistance;2023-10